Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.62 |
| ▸ | CTSB | P07858 | 3/20 | 0.62 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 7/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19138299 | 1.00 | CAPN1 (0.62) | CAPN1CTSBXIAPELANESLC6A2 | |
| SCHEMBL19138367 | 1.00 | CAPN1 (0.62) | CAPN1CTSBXIAPELANESLC6A2 | |
| SCHEMBL19138277 | 1.00 | CAPN1 (0.62) | CAPN1CTSBXIAPELANESLC6A2 | |
| SCHEMBL16695968 | 0.89 | CAPN1 (0.61) | CAPN1CTSBXIAPELANESLC6A2 | |
| SCHEMBL16696001 | 0.88 | CAPN1 (0.49) | CAPN1CTSBSLC6A2 | |
| SCHEMBL19138297 | 0.88 | CAPN1 (0.57) | CAPN1CTSBXIAPELANESLC6A2 | |
| SCHEMBL19138298 | 0.88 | CAPN1 (0.57) | CAPN1CTSBXIAPELANESLC6A2 | |
| SCHEMBL19138353 | 0.88 | CAPN1 (0.57) | CAPN1CTSBXIAPELANESLC6A2 | |
| SCHEMBL19138322 | 0.88 | CAPN1 (0.57) | CAPN1CTSBXIAPELANESLC6A2 | |
| Rapastinel SCHEMBL23753673 | 0.87 | CAPN1 (0.59) | CAPN1CTSBXIAPELANESLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3916003-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | Naurex, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3171941-B1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20180258139-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2018-09-13 | — | — | US | disclosed |
| US-9994614-B2 | N-methyl-D-aspartate receptor modulators and methods of making and using same | NAUREX, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170210779-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258139-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | GRIN1, GRIN2A, GRIN3A | CAPN1 607/4885CTSB 3811/4885XIAP 1851/4885 |
| US-20170210779-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | GRIN1, GRIN2A, GRIN3A | CAPN1 607/4885CTSB 3811/4885XIAP 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.